{"entity":{"id":"nct07411599","kind":"trial","name":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Rela","aka":[],"tldr":"A phase 1/2 trial of cyclophosphamide, fludarabine and cetuximab in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.","summary":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\") is a phase 1/2, interventional study registered as NCT07411599 by M.D. Anderson Cancer Center, with a registry enrolment figure of 28 participants, started 2026-04-20 and due to reach its primary completion in 2028-11-15. Interventions recorded: Cyclophosphamide; Fludarabine; Cetuximab; NK Cells. Conditions listed: Colorectal Cancer; Peritoneal Metastases; Carcinomatosis. Primary outcome: Safety and adverse events (AEs. Colorectal eligibility wording from the registry: \"o History of hysterectomy or bilateral salpingo-oophorectomy\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07411599","url":"https://clinicaltrials.gov/study/NCT07411599"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","monoclonal-antibody"],"targets":[],"drugs":["cyclophosphamide","fludarabine","cetuximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07411599","phase":"1/2","setting":"Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial (\"Chip-CRC Trial\")","sponsor":"M.D. Anderson Cancer Center","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07411599/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}